muscle degeneration

An experimental myostatin-blocking drug for sporadic inclusion-body myositis will get special attention from the U.S. Food and Drug Administration

posted on August 26, 2013 - 3:45pm
Update (July 16, 2014): Some people have reported difficulty getting information about this trial when contacting the trial sites or Novartis. MDA is looking into these matters.

New evidence casts doubt on the role of tau protein in inclusion-body myositis

posted on August 27, 2009 - 11:16am
Abnormal accumulation of a protein called "tau" has been considered by many to contribute to muscle degeneration in inclusion-body myositis (IBM). But recently, MDA grantee Steven Greenberg and colleagues at Brigham and Women's Hospital and Harvard Medical School in Boston have cast doubt on this purported disease mechanism and say it's too early to develop drugs for IBM based on it.